Glandokort
/ Khavinson-tradition adrenal cortex bioregulatorALIAS · Glandokort · Adrenal peptide bioregulator
Terms in this page you can click for a plain-English popup: , , , , , , , .
Tier 4. Khavinson-tradition vendor preparation positioned as an adrenal-cortex-derived bioregulator. No PubMed-indexed primary literature on Glandokort as a distinct molecular entity; the evidence base is class-level Russian-origin literature on tissue-extract peptide bioregulators from the Saint-Petersburg Institute of Bioregulation and Gerontology.
Glandokort is described in vendor materials as a short-peptide preparation derived from adrenal-cortex tissue, intended within the Khavinson-tradition framework to regulate adrenal-cortex cell function and steroidogenic gene expression. The exact peptide composition disclosed by vendors is variable and the active sequence has not been characterised in independent primary literature.
Tier 4. No PubMed-indexed primary literature on Glandokort as a distinct preparation. Russian-origin class-level reviews from the Khavinson group group adrenal bioregulators with other tissue-specific peptide bioregulators in support of the broader tissue-specific-peptide framework.
No formal human safety database. Animal-tissue-derived short-peptide preparations carry general class concerns (identity, purity, endotoxin, source-tissue prion / viral risk) that are not addressed by vendor channels in the absence of regulated pharmaceutical manufacturing controls.
Regulatory status
- FDA status:
- Not FDA-approved
The Khavinson school (Saint-Petersburg Institute of Bioregulation and Gerontology) has published an extensive body of work on short-peptide 'bioregulators' derived from animal-tissue extracts, with a unifying claim that tissue-specific tetrapeptides (and shorter motifs) regulate gene expression and tissue-specific cell function. The corpus is Russian-origin and substantially self-cited; independent Western replication of the foundational findings has not been established.
Vendor product identity is not externally verifiable: the disclosed active sequence varies between sellers and the manufacturing source (animal-tissue extract vs synthetic short peptide) is not always transparent. The adrenal-cortex tissue-source claim has additional implications for cross-species exposure that vendor channels do not systematically address.